## **Price Sensitive Information**

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC held on Wednesday, 29<sup>th</sup> January 2025 at 3.15 PM at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka -1223 has approved the Un-audited Half Yearly Financial Statements of the Company for the period ended 31<sup>st</sup> December 2024 and has taken the following decisions:

## 1) Financial Information:

Earning Per Share (EPS) : Tk. 3.47
Net Asset Value Per Share (NAVPS) : Tk. 28.23
Net Operating Cash Flow Per Share (NOCFPS): Tk. 6.38

## 2) The Comparative statement of financial information:

Pariticulars	Jul'24-Dec'24	Jul'23-Dec'23	Oct'24-Dec'24	Oct'23-Dec'23
Earning Per Share (EPS)	Tk. 3.47	Tk. 3.25	Tk. 1.91	Tk. 1.65
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 6.38	Tk. (2.34)	-	-
Pariticulars	As at 31 Dec' 2	24	As at 30 Jun' 2	4
Net Asset Value Per Share (NAVPS)	Tk. 28.23		Tk. 26.37	

Date: 29-01-2025

By the order of the Board of Directors

S/D

Md. Sahabuddin FCS Company Secretary

BEACON

Pharmaceuticals PLC

BEACON Business Centre:
9/B/2 Toyenbee Circular Road, Motifheel, Dhaka-1223

3C X 4 Inch